Meeting
2013 ASCO Annual Meeting
Association of body mass index (BMI) with overall survival (OS) in patients (pts) with metastatic colorectal cancer (mCRC) who received targeted therapies (TT).
Authors
Gargi Surendra Patel
Deptartment of Medical Oncology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Adelaide, Australia
Gargi Surendra Patel , Shahid Ullah , Carol Beeke , Paul Hakendorf , Rob Padbury , Timothy Jay Price , Christos Stelios Karapetis
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Colorectal) Cancer
Track
Gastrointestinal Cancer—Colorectal and Anal
Sub Track
Colorectal Cancer
Citation
J Clin Oncol 31, 2013 (suppl; abstr 3592)
DOI
10.1200/jco.2013.31.15_suppl.3592
Abstract #
3592
Poster Bd #
8B
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Predictive value of CDC37 gene expression for targeted therapy in metastatic colorectal cancer (mCRC).
First Author: Hiroyuki Arai
Poster
2017 Gastrointestinal Cancers Symposium
Effect of subsequent chemotherapy on overall survival in first-line chemotherapy with targeted agents for patients with metastatic colorectal cancer: Systematic review and meta-analysis of randomized control trials.
First Author: Daisuke Sakai
Poster
2014 ASCO Annual Meeting
Impact of chemotherapy partner on efficacy of targeted therapy in metastatic colorectal cancer (mCRC): A meta-analysis.
First Author: David Chan
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Front-line use of FOLFOXIRI plus bevacizumab and subsequent therapies in metastatic colorectal cancer (mCRC).
First Author: Afsaneh Barzi